CC-chemokine receptor 7 (CCR7), a chemokine receptor required for transmigration into lymphoid organs, is only expressed by naive and central memory T cells. T cells with a capacity of homing into lymphoid organs can initiate acute graft-versus-host disease (GVHD) in mice and respond vigorously in vitro to alloantigens in humans, but their impact on clinical outcomes is unknown. We evaluated prospectively the distribution of naive, central memory and CCR7 neg memory T-cell subsets in 39 bone marrow and 23 granulocyte colonystimulating factor-mobilized peripheral blood stem cell allografts and investigated their impact on patient outcomes. Ranges of the relative proportions of CCR7 þ cells within CD4 þ and CD8 þ T-cell populations were broad, but did not differ between the two sources of allografts. By multivariate analysis, high percentage of donor-derived CD4 þ CCR7 þ T cells (473.5%) significantly correlated with incidence, earliness of onset and severity of acute GVHD, conferring the highest adjusted hazard ratio (HR ¼ 3.9; 95% confidence interval 1.4-10.8; P ¼ 0.008) without interfering in other clinical events, especially chronic GVHD and relapse. Determination of the percentage of CD4 þ CCR7 þ T cells in the graft provides a predictive indicator of acute GVHD. Partial depletion of this subset may reduce the risk of acute GVHD while preserving immunotherapeutic effects.
Introduction
Allogeneic stem cell transplantation (allo-SCT) provides the potential for T-cell therapy not available in unmodified autologous transplants. Donor-derived mature T cells are involved in engraftment, graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) activity, 1 and thus play a major role in determining clinical outcome. However, separation of the detrimental and beneficial effects conferred by donor-derived T cells remains an elusive clinical goal.
Acute GVHD necessitates the migration of donor T cells to secondary lymphoid organs, where they can respond to host alloantigen-presenting cells. Their progeny disseminates out of the lymphoid compartment and infiltrates target organs in the final effector phase. [2] [3] [4] Transmigration is a multistep process involving selectin-dependent tethering followed by a triggering event permitting firm integrin-mediated adhesion. Among surface molecules expressed by T cells, L-selectin (CD62L), certain integrins and the CC-chemokine receptor 7 (CCR7) are crucial for regulating their recirculation to lymphoid organs. Use of CCR7-deficient mice has evidenced the key role of this receptor for the initiation of alloimmune responses, 5, 6 and use of an antagonist can modulate GVHD in unmanipulated mice. 7 Likewise, targeting both L-selectin and a a4 integrin can delay acute GVHD in mice. [8] [9] [10] In humans and in mice, CD62L and CCR7 are differentially expressed by T-cell subpopulations, conferring them distinct migratory and immediate effector capacities. Naive and central memory (T CM ) cells constitutively coexpress CCR7 and CD62L. Effector memory (T EM ) and terminally differentiated memory cells (T TD , which are mainly found within the CD8 þ T-cell pool in humans) have lost CCR7 expression, but a significant percentage may retain CD62L expression. 11, 12 Experiments in unprimed mice have demonstrated that CD62L þ T-lymphocytes could induce GVHD in allogeneic hosts, whereas CD62L neg memory T cells could not. 13, 14 Transfer of CD62L þ T CM cells could also prevent the initiation of transplantation tolerance. 15 In humans, it has been shown that CD4 þ CD62L þ T cells responded better to alloantigens than the CD62L neg memory subsets in both proliferation and cytotoxicity assays, 16 and in vitro-generated T CM appeared to be more potent than T EM in an experimental model of GVHD. 17 Thus, the initiation of GVHD seems to depend on the representation of alloreactive cells within naive and/or central memory subsets in the graft, but no clinical study has yet sustained these experimental or in vitro data.
The distribution of naive and memory T cells in the peripheral lymphocyte compartment and the composition of the memory T-cell pool differ markedly between individuals, depending on their past histories of antigen stimulations. [18] [19] [20] [21] Many studies have reported on CD3 þ T cells and their CD4 þ and CD8 þ subpopulations in bone marrow stem cell (BMSC) or granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cell (PBSC) allografts. However, to our knowledge, none has investigated the distribution of naive, T CM , T EM and T TD subsets. Given this background, we prospectively investigated the impact of naive and memory T-cell subsets infused on incidences of acute and chronic GVHD, relapse and survival after unmanipulated allo-SCT.
Donors, patients and methods

Donors and patients
The study started on September 2003 through September 2005. Patients who underwent a syngeneic transplantation (n ¼ 2) and those who received anti-thymoglobulin with their conditioning (n ¼ 3) were excluded from the study. The remaining 62 consecutive patients who underwent an allo-SCT in our Hematopoietic Stem Cell Transplantation Unit were included. The study design has been approved by the ethics committee of the Lille University Hospital, and all donors and recipients (and parents of children) have given their informed consent.
The main characteristics of patients and donors are summarized in Table 1 . Forty patients had an acute leukemia; all but three patients were in complete remission at the time of transplantation. The other patients had chronic myeloid leukemia in chronic phase (n ¼ 4), myelodysplastic syndrome without blast crisis (n ¼ 4) or chronic lymphoproliferative disorder (n ¼ 14). Most patients received a myeloablative regimen either with fractioned total body irradiation (TBI, 12 Gy) plus cyclophosphamide (60 mg/kg) or with busulfan plus cyclophosphamide (200 mg/kg). The remaining 17 patients received non-myeloablative conditioning consisting of fludarabine (25 mg/m 2 /day Â 3) and TBI (2 Gy). GVHD prophylaxis was based on cyclosporine A (CsA) plus methotrexate in patients with myeloablative conditioning and CsA plus mycophenolate mofetil in the others.
Donors were human leukocyte antigen (HLA)-identical sibling (n ¼ 41), unrelated with HLA-A, -B, -Cw, -DR and -DQ identity at allelic level (so-called 10/10; n ¼ 19), or unrelated with one mismatch in HLA-Cw (9/10; n ¼ 2). They all were negative for HIV serology and p24 antigen, HTLV 1-2 , syphilis, and hepatitis B and C. Almost all donors were seropositive for both EpsteinBarr virus (n ¼ 59) and variceela zoster virus (n ¼ 44); around half were seropositive for HSV (n ¼ 34) or cytomegalovirus (n ¼ 30).
Harvest procedures and transplantation modalities
Bone marrow allografts were procured by aspiration from the posterior iliac crests, and a minimum of 3 Â 10 8 nucleated cells/ kg of recipient weight (RW) was collected. In case of major ABO donor/recipient incompatibility, red blood cells were removed from the BMSC graft. PBSCs were mobilized with G-SCF at the dose of 10 mg/kg of donor weight/day from day À5 before stem cell collection. A minimum of 3 Â 10 6 CD34 þ cells/kg of RW was collected.
Thirty-nine (63%) patients received BMSC, and the 23 others received PBSC. None of the grafts has been depleted of T cells. Patient and donor age were fairly similar (medians of 40 years each). No patient was lost to follow-up. Patients were monitored prospectively in terms of clinical post-graft complications, graft rejection, relapse and survival. Acute GVHD was scored according to the modified clinical staging and grading system described by Przepiorka et al. 22 Front-line treatment of acute GVHD consisted of corticosteroids at the dose of 2 mg/day for 14 days, followed by dose tapering of 20% per week. Patients who developed refractory acute GVHD received high-dose corticosteroid or anti-IL2R antibodies, as clinically indicated. Chronic GVHD was classified according to standard criteria, which include limited and extensive grades.
Multiparameter flow cytometric analysis of graft composition
Samples were stained without further separation shortly after collection, using directly conjugated antibodies to CD3, CD4, CD8, CD19, CD45, CD45RA, CD56, CCR7 and isotype controls. All reagents and instrumentation were from Beckman Coulter (Fullerton, CA, USA), with the exception of the monoclonal antibody to CCR7, from R&D systems (Minneapolis, One-way mixed leukocyte response in healthy control subjects 
Statistical analysis
For the graft composition study, the results are expressed as medians and interquartile ranges and compared using nonparametric analysis (Mann-Whitney U-test or Kruskal-Wallis test, as appropriate). For patients' outcome study, the analyses were performed in the survival analysis framework (reference date: 1 October 2005). Overall survival (OS) was defined as the time elapsed from allo-SCT to death, whatever the cause of death; event-free survival (EFS) as survival from allo-SCT with no evidence of relapse; and transplantation-related mortality (TRM) as death resulting from the graft procedure without evidence of relapse. The time from transplantation to the onset of acute GVHD was considered for analysis in patients who developed acute GVHD; those who did not were censured at day þ 100 or at the date of death if it occurred first. All patients were evaluated for chronic GVHD if their survival exceeded 100 days post-transplant. Probabilities were estimated by the KaplanMeier product-limit method. 23 For each criterion, univariate analyses were performed using log-rank tests. 24 Factors identified in these analyses were brought into a multivariate analysis using Cox proportional-hazards model. 25 All donor and recipient characteristics (as presented in Table 1 ) and the absolute counts and percentages of all cell subsets composing the allograft (as in Table 2 ) were considered for analyses. Categorical variables were compared using w 2 test or Fisher's exact test, as appropriate. For allogeneic mixed leukocyte responses (MLRs), comparisons were performed using two-way analysis of variance. All analyses were performed with SPSS software (SPSS v 11.5, Chicago, IL, USA). Two-sided tests were used, and Po0.05 was considered statistically significant.
Results
Graft composition
As expected, absolute cell counts were X30-fold higher in PBSC than in BMSC grafts (Table 2) . Accordingly, absolute counts of all lymphocyte subsets were higher in PBSC. Further comparisons were therefore made on relative values. BMSC and PBSC grafts contained similar percentages of CD3 þ cells (Table 2) , CD19 þ cells and CD56 þ cells (data not shown). Whatever the graft source, the balance of individual memory subsets was different between the CD4 þ and the CD8 þ pools: T CM and T EM predominated within the CD4 þ memory pool, whereas the CD8 þ memory pool comprised mainly CCR7 neg subsets (Table 2 ). In each memory pool, only the minor subset (CD4 þ T TD and CD8
þ T CM , respectively) was differently distributed between BMSC and PBSC. The percentages of CCR7-expressing cells did not differ significantly between BMSC and PBSC. However, wide interdonor variations were found, irrespective of graft source, resulting in a broad range of CCR7 þ lymphocytes among all graft specimens, with extremes of 29-95% within CD4 þ T cells and 4.5-94% within CD8 þ T cells.
Influence of graft composition on acute GVHD
Twenty patients developed acute GVHD (projected incidence of 3376%), including eight patients with grade II, three patients with grade III and three patients with grade IV. Neither the source of the graft (BMSC versus PBSC) nor numbers of T cells infused (total CD3 þ T cells and their CD4 þ and CD8 þ populations) were predictive of acute GVHD (Table 3) . Only two independent risk factors were evidenced by multivariate analysis (Table 4) , donor type (related versus unrelated) and the relative proportion of CD4 þ CCR7 þ T cells infused (categorized by the median percentage of cells in the graft). Thus, receiving 473.5% of CD4 þ CCR7 þ T cells conferred the highest adjusted hazard ratio (HR ¼ 3.9; 95% confidence interval (CI) 1.4-10.8; P ¼ 0.006).
To get further insight, patients were recategorized as receiving a percentage of CD4 þ CCR7 þ T cells falling within the first, second, third or fourth quartile: both likelihood of acute GVHD and earliness of its onset increased with the percentage of CD4 þ CCR7 þ T cells infused (Figure 1a) . Accordingly, the percentage of CD4 þ CCR7 þ T cells infused was correlated to incidence and severity of acute GVHD: thus, patients without or only grade I GVHD had a median of 70%, whereas those who developed grade II and III-IV acute GVHD had medians of 74 and 93%, respectively (P ¼ 0.001) (Figure 1b) .
Influence of graft composition on chronic GVHD
Twenty-two of the 55 assessable patients (who survived beyond day 100) developed chronic GVHD, including 10 with extensive grade. Patients who received PBSC developed more often chronic GVHD (70%) than did patients who received BMSC (24%) (P ¼ 0.002, Fisher's exact test). By multivariate analysis, only PBSC as source of graft yielded a high adjusted HR for chronic GVHD (HR ¼ 4.1; 95% CI 1.6-10.1) ( Table 4 ). The relative proportions of CD4 þ CCR7 þ cells infused had no demonstrable influence on incidence of chronic GVHD (Figure 2a ). There was also no association with CD8 þ CCR7 þ cells and their naive and central memory subsets. By using less
demanding (univariate) analyses, incidence of chronic GVHD was associated to quantities of CD34 þ and CD3 þ cells infused (data not shown).
Influence of graft composition on relapse and survival
On the reference date of 1 October 2005, median time of follow-up from allo-SCT was 374 days (range, 101-739 days), and 44 patients were alive. Nine patients died of relapse and nine of TRM (four acute GVHD, two interstitial pneumonia, 2 second rejections and one veno-occlusive disease of the liver). The estimated 1-year OS, EFS and TRM rates were 6578, 5977 and 1575%, respectively. None was influenced by the relative proportion of CD4 þ CCR7 þ T cells infused (Table 4 ). In particular, relapse categorized by the quartiles of CD4 þ CCR7 þ T cells infused yielded overlapping curves (Figure 2b ).
Influence of the relative proportion of CD4
þ CCR7 þ
T cells on in vitro alloresponses
One-way mixed leukocyte cultures were performed comparing responder cells from healthy volunteers chosen for having a high (X80%) or a low (p55%) percentage of CCR7 þ cells within their CD4
þ T cells. Irrespective of individual variations according to the MLR combinations tested, PBMCs comprising abundant CD4 þ CCR7 þ T cells consistently responded with a higher proliferation rate than those with fewer CD4 þ CCR7 þ T cells (Po0.001) (Figure 3 ), whereas no significant association was found between allo-MLR responsiveness and the percentage of CD8 þ CCR7 þ T cells.
Discussion
To our knowledge, this is the first comparative analysis of naive and memory T-cell subsets composing PBSC and BMSC grafts, as defined by their profiles of CD45RA and CCR7 expression, with assessment of their impact on clinical outcome following allo-SCT. Our findings are as follows: (i) ranges of the relative proportions of CCR7-expressing (naive and central memory) CD4 þ and CD8 þ T cells are broad, but do not differ between BMSC and PBSC allografts; (ii) incidence and severity of acute GVHD, both increase with the relative proportion of CD4 þ CCR7 þ T cells infused and (iii) chronic GVHD and other transplant events, including relapse, do not appear to be influenced by the balance of naive and memory T cells infused. Our results add further support to the notion that T cells capable We preferred to assess CCR7 expression, instead of CD62L that has been utilized in the cell transfer experiments and in vitro assays presented in the introduction because, technically, CCR7 expression discriminates better naive and central memory cells from effector and terminally differentiated memory cells, as a conspicuous fraction of T EM and T TD cells may keep CD62L expression. 27 In addition, CCR7 is required not only for chemotaxis and triggering integrin-mediated firm adhesion before transmigration but also for directing T cells to their corresponding functional microenvironment in the lymphoid organs. Interfering with CCR7 alone can indeed modulate alloimmune responses, whereas targeting L-selectin alone does not suffice to delay acute GVHD in mice. [7] [8] [9] [10] As reported by others, [28] [29] [30] [31] [32] absolute lymphocyte counts were much higher in PBSC. Our data bring new information by showing that frequencies of the naive and the major memory T-cell subsets did not differ significantly between PBSC and BMSC grafts. The percentage of CCR7-expressing cells was higher in the CD4 þ than the CD8 þ population, whatever the graft source. Predominance of CCR7 þ cells within the CD4 þ population was also described in peripheral blood.
11,21
We observed an acute GVHD rate similar to those usually observed with allo-SCT in patients comparable to ours. One approach to evaluating whether, and to what extent, CCR7 þ T cells can be effective at initiating acute GVHD in human patients is to analyze whether the absolute numbers or the proportion of these cells correlates with incidences of GVHD. By multivariate analysis, patients who developed acute GVHD had received a higher percentage of CD4 þ CCR7 þ T cells, which conferred a higher adjusted HR than unrelated donor type, the only other significant risk factor identified in our patients. Not only incidence but also earliness of onset and Table 3 Distribution of allogeneic T-cell subsets infused according to the occurrence of acute GVHD þ CCR7 þ T cells infused and the development and severity of acute GVHD might reflect the predominant distribution of alloreactive T cells in the naive and central memory subsets, as described in experimental models for naive and central memory subsets. 13, 16, 33 In vitro alloresponses could not be tested in our patients, but we performed one-way mixed leukocyte cultures to compare healthy control subjects with a low or a high percentage of CD4 þ CCR7 þ T cells. In vitro alloresponses were consistently higher when responder PBMCs contained more CD4 þ CCR7 þ T cells. This finding is consistent with results reported on the overlapping population of CD4 þ CD62L þ T cells. 16 In the current study, acute GVHD was correlated to cells expressing CCR7 only within the CD4 þ population. This is consistent with two recent reports. In vitro, no difference was found between alloresponses of fractionated CD8 þ CD62L þ and CD8 þ CD62L neg subsets, which were even lower than those of the poor responsive CD4 þ CD62L neg human subset. 16 In vivo, tracking donor cells during acute GVHD in mice has demonstrated that proliferation of CD4 þ T cells preceded that of CD8 þ T cells in murine lymphoid organs. 2 The importance of this subset in initiating acute GVHD is presumably linked to the necessary help that CD4 þ T cells provide to the generation of long-term CD8 þ responses. 34, 35 The percentage, but not the cell dose, of CD4 þ CCR7 þ T cells infused, was correlated with acute GVHD. Numerous studies have shown that incidence of acute GVHD was not higher after PBSC, despite the infusion of higher T-cell doses than in marrow grafts. 36, 37 Acute GVHD can be induced by as low as 1 Â 10
5
T cells/kg in the setting of HLA-matched allo-SCT, [38] [39] [40] and even less in HLA-disparate transplantation. 41 A modulating effect of G-CSF notwithstanding, these observations suggest that once a threshold dose of cells is transplanted, acute GVHD may not be directly proportional to the quantity of T cells infused. The extensive replicative capacity of CD4 þ naive and T CM subsets 11, 42 can explain why their frequency, instead of absolute number, influences incidence and severity of acute GVHD.
Contrary to acute GVHD, we found no link between chronic GVHD and CCR7-expressing cells or the distribution of naive and memory subsets in the allograft. Besides time of onset, Donor CD4 þ CCR7 þ T cells and acute GVHD I Yakoub-Agha et al chronic and acute GVHD differ by many clinical and pathobiological characteristics. [43] [44] [45] First, in this as in other reports, 37, 46 incidence of chronic GVHD was higher after PBSC transplantation, whereas acute GVHD was as frequent as after BMSC grafts, and indeed graft source was the only predictive factor identified in our donor-patient pairs. Second, not all acute GVHD proceed to chronic GVHD and chronic GVHD can occur without prior acute GVHD. Third, chronic GVHD involves pathogenic autoreactivity in addition to alloreactivity. Aberrant response to autoantigens is thought to result from two mechanisms. One is homeostatic proliferation of donor mature T cells. In this study, all but two donor-recipient pairs were HLA-identical, and the remaining two had only one HLA-Cw mismatch. Donor T cells were then exposed to self-peptides presented by non-disparate HLA molecules in a lymphopenic host, which can favor the expansion of T cells with higher affinity for self and break self-tolerance. 47 The other mechanism is aberrant thymopoiesis, leading to impaired negative selection of autoreactive clones derived from donor stem cells and/or reduced generation of regulatory T cells. [48] [49] [50] [51] [52] The influence of this mechanism has recently been evidenced in the clinical setting, as T-cell depletion of allografts could not reduce the incidence of chronic GVHD. 53 It is conceivable that the higher number of CD34 þ cells in PBSC could generate more autoreactive post-thymic T cells, thereby increasing the risk of chronic GVHD and confounding the contribution of alloreactive CCR7 þ donor T cells. GVL activity and chronic (rather than acute) GVHD are often overlapping, [54] [55] [56] which might account in part for our observation that, like chronic GVHD, relapse was not significantly associated with the percentage of CD4 þ CCR7 þ T cells infused. Moreover, there are indications that GVHD can be separated from GVL effects. 57 As regards T cells, CD62L neg donor T cells can mediate GVL activity in mice and, in humans, CD8 þ memory subsets contain cells specific for antigens overexpressed in tumors. 58, 59 Finally, interactions between graft-and non-graft-related factors are likely to influence chronic GVHD, TRM, relapse and survival, whereas acute GVHD depends primarily on donor T-cell alloresponses.
Conclusion
This study provides the first indication that receiving a high percentage of CD4 þ CCR7 þ T cells influences incidence and severity of acute GVHD without influencing other transplantation events. Determining the proportion of CD4 þ CCR7 þ T cells in the allograft might therefore provide an important predictive indicator of acute GVHD. Together with murine experiments and in vitro observations in humans, our prospective study indicates that alloreactive cells predominate within the CCR7-positive subsets and lends support to approaches of selective T-cell depletion for prevention of acute GVHD. As patients receiving low percentages of CD4 þ CCR7 þ T cells had less acute GVHD without increased relapse and TRM rates, a partial depletion of CD4 þ CCR7 þ T cells might suffice to prevent acute GVHD without compromising therapeutic efficiency and immune reconstitution. 
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